Pavla
Pavla Jendelová, Stredokluky CZ
Patent application number | Description | Published |
---|---|---|
20090309597 | Superparamagnetic Nanoparticles Based on Iron Oxides with Modified Surface, Method of Their Preparation and Application - The subject of the invention is superparamagnetic nanoparticle probes based on iron oxides, to advantage magnetite or maghemite, with modified surface, coated with mono-, di- or polysaccharides from the group including D-arabinose, D-glucose, D-galactose, D-mannose, lactose, maltose, dextrans and dextrins, or with amino acids or poly(amino acid)s from the group including alanine, glycine, glutamine, asparagine, histidine, arginine, L-lysine, aspartic and glutamic acid or with synthetic polymers based on (meth)acrylic acid and their derivatives selected from the group containing poly(N,N-dimethylacrylamide), poly(N,N-dimethylmethacrylamide), poly(N,N-diethylacrylamide), poly(N,N-diethylmethacrylamide), poly(N-isopropylacrylamide), poly(N-isopropylmethacrylamide), which form a colloid consisting of particles with narrow distribution with polydispersity index smaller than 1.3, the average size of which amounts to 0.5-30 nm, to advantage 1-10 nm, the iron content is 70-99.9 wt. %, to advantage 90 wt. %, the modification agent content 0.1-30 wt. %, to advantage 10 wt. %. | 12-17-2009 |
Pavla Jendelová, Stredokluky CZ
Patent application number | Description | Published |
---|---|---|
20090309597 | Superparamagnetic Nanoparticles Based on Iron Oxides with Modified Surface, Method of Their Preparation and Application - The subject of the invention is superparamagnetic nanoparticle probes based on iron oxides, to advantage magnetite or maghemite, with modified surface, coated with mono-, di- or polysaccharides from the group including D-arabinose, D-glucose, D-galactose, D-mannose, lactose, maltose, dextrans and dextrins, or with amino acids or poly(amino acid)s from the group including alanine, glycine, glutamine, asparagine, histidine, arginine, L-lysine, aspartic and glutamic acid or with synthetic polymers based on (meth)acrylic acid and their derivatives selected from the group containing poly(N,N-dimethylacrylamide), poly(N,N-dimethylmethacrylamide), poly(N,N-diethylacrylamide), poly(N,N-diethylmethacrylamide), poly(N-isopropylacrylamide), poly(N-isopropylmethacrylamide), which form a colloid consisting of particles with narrow distribution with polydispersity index smaller than 1.3, the average size of which amounts to 0.5-30 nm, to advantage 1-10 nm, the iron content is 70-99.9 wt. %, to advantage 90 wt. %, the modification agent content 0.1-30 wt. %, to advantage 10 wt. %. | 12-17-2009 |
Pavla Kopeckova, Salt Lake City, UT US
Patent application number | Description | Published |
---|---|---|
20110085979 | CONJUGATE OF A POLYMER, AN ANTI-ANGIOGENESIS AGENT AND A TARGETING MOIETY, AND USES THEREOF IN THE TREATMENT OF BONE RELATED ANGIOGENESIS CONDITIONS - Conjugates of hydroxypropyl methacrylamide (HPMA)-derived copolymers having attached thereto TNP-470 and a high load (e.g., higher than 3 mol %) of alendronate (ALN), and processes of preparing same are disclosed. | 04-14-2011 |
20130156722 | POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF - Described herein are biodegradable drug delivery conjugates for effectively delivering bioactive agents to a subject. The drug delivery conjugates comprise a water-soluble high molecular weight linear biodegradable polymer backbone comprising a plurality of linear water-soluble polymeric segments connected to one another by a first (main-chain) cleavable linker, wherein a bioactive agent is covalently bonded to at least one water-soluble polymeric segment, at least one cleavable linker, or a combination thereof. The conjugates possess numerous advantages over prior art delivery conjugates. Also described herein are methods for making and using the conjugates. | 06-20-2013 |
20140212357 | CONJUGATE OF A POLYMER, AN ANTI-ANGIOGENESIS AGENT AND A TARGETING MOIETY, AND USES THEREOF IN THE TREATMENT OF BONE RELATED ANGIOGENESIS CONDITIONS - Conjugates of hydroxypropyl methacrylamide (HPMA)-derived copolymers having attached thereto TNP-470 and a high load (e.g., higher than 3 mol %) of alendronate (ALN), and processes of preparing same are disclosed. | 07-31-2014 |
Pavla Kopecková, Salt Lake City, UT US
Patent application number | Description | Published |
---|---|---|
20130156722 | POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF - Described herein are biodegradable drug delivery conjugates for effectively delivering bioactive agents to a subject. The drug delivery conjugates comprise a water-soluble high molecular weight linear biodegradable polymer backbone comprising a plurality of linear water-soluble polymeric segments connected to one another by a first (main-chain) cleavable linker, wherein a bioactive agent is covalently bonded to at least one water-soluble polymeric segment, at least one cleavable linker, or a combination thereof. The conjugates possess numerous advantages over prior art delivery conjugates. Also described herein are methods for making and using the conjugates. | 06-20-2013 |
Pavla Pouckova, Dobrichovice CZ
Patent application number | Description | Published |
---|---|---|
20100055165 | LIPOSOMAL GEL PHTHALOCYANINE PREPARATION FOR PHOTODYNAMIC THERAPY OF TUMORS AND ITS MANUFACTURING - Liposomal gel hydrophobic phthalocyanine (FCH) preparation for photodynamic therapy of tumors and other diseases is composed of lecithin liposomes or liposomes on the basis of other lipids, with incorporated curing drug, which can be chosen either from a group including hydrophobic hydroxyaluminum phthalocyanine, hydrophobic aluminum phthalocyanine, hydrophobic zinc phthalocyanine, hydrophobic silicone phthalocyanine, or organic silicone phthalocyanine, or hydrophobic phthalocyanine without the core metal; while resulting liposomes are mixed in ratios of 10:1 to 1:10 with a translucent gel, advantageously on the basis of carboxymethylcellulose. The added curing drug can be coated by glucose or other saccharides, by polyethylenglycol or other usable polymers, as lecithin or other lipids, or by sodium chloride or other salts usable in pharmacology. Liposomal gel hydrophobic phthalocyanine (FCH) preparation is manufactured on the following schema: Lecithin or other lipid of a pharmacological purity at concentration between 10 to 40 mg per ml of sterile isotonic solution is fluidised on a microfluidizer in particular chamber to the final particle size smaller than 1000 nm, in temperature higher than 0° C. and a pressure at 500 to 2000 Bar; then while stirring the curing drug or the treated curing drug is added in the ratio of 5:1 to 0.1:1 in relation to the lecithin or other lipid; the resulting suspension is again fludized on a microfludizer in particular smaller chamber to the final particle size smaller than 500 nanometer, with pressure at least 1000 to 2000 Bar, in temperature higher than 0° C.; the resulting suspension is then mixed with a translucent gel in ratios of 10:1 to 1:10; Alternatively, first lecithin or other lipid of a pharmacological purity at concentration between 10 to 40 mg per ml of sterile isotonic solution is microfludized on a microfluidizer in particular chamber to the final particle size smaller than 1000 nm, a pressure at least 1000 to 2000 Bar and temperature higher than 0° C.; Afterwards, in parallel the curing drug or the treated curing drug is separately microfluidized in amounts corresponding to the ratio of 5:1 to 0.1:1 in relation to the lecithin or other lipid in an equal volume of fluid, advantageously on the basis of sterile isotonic solution to the final particle size smaller than 1000 nanometer, and with pressure at 1000 to 2000 Bar; Afterwards both microfludized components are mixed together and again microfludized on a microfludizer in particular chamber with a pressure at 1000 to 2000 Bar and temperature higher than 0° C. to the final particle size maximum of 500 nanometer, the resulting suspension is fluidised on a microfluidizer in a particular smaller chamber with a pressure at least 1000 to 2000 Bar and temperature higher than 0° C. to the final particle size smaller then 500 nm, the resulting suspension is then mixed with a translucent gel in ratios of 10:1 to 1:10; Alternatively, Lecithin or other lipid in the pharmacological purity at the concentration of 10 to 40 mg per milliliter of sterile isotonic solution is first treated by extrusion across the filters with a size 10 to 500 nm together with the curing drug or the treated curing drug in the ratio of 5:1 to 0.1:1 related to the lecithin or other lipid; and the resulting suspension is again fluidised on a microfluidizer in a particular chamber with a pressure at least 1000 to 2000 Bar and temperature higher than 0° C. to the final particle size smaller then 500 nm, with a pressure at least 1000 to 2000 Bar and temperature higher than 0° C., the resulting suspension is mixed with a translucent pharmaceutical gel in a ratio of 10:1 to 1:10. | 03-04-2010 |
Pavla Prichystalova, Brno CZ
Patent application number | Description | Published |
---|---|---|
20110251739 | DISTRIBUTED FLY-BY-WIRE SYSTEM - A system includes a plurality of fly-by-wire control units to control flight control surfaces of an airplane, wherein each control unit is adapted to operate independently of other control units and directly control an actuator to control a control surface as a function of direct pilot control device input. | 10-13-2011 |
Pavla Spácilová, Ostrava CZ
Patent application number | Description | Published |
---|---|---|
20110218167 | Triterpenoid 2-deoxy Glycosides, Method of Preparation Thereof and Use Thereof as Medicaments - The invention describes novel triterpenoid 2-deoxy glycosides of general formula I, wherein at least one of the substituents X | 09-08-2011 |
Pavla Vandrovcova, Ceske Budejovice CZ
Patent application number | Description | Published |
---|---|---|
20150121833 | CORD EYE - The invention relates to a rope end which is spliced, whereby a loop is formed, comprising a rope end piece folded back in order to form the loop and a rope section leading to the loop, wherein a spliced area is provided in which the rope end piece is guided within the rope section leading to the loop, and wherein the rope is a core/sheath rope. The rope end according to the invention is characterized in that, in the rope end piece, part of the core, preferably the entire core, is removed in the spliced area, that a load-bearing sewing of the rope end piece to the rope section leading to the loop is provided in the spliced area and that a load-bearing sewing is provided in an area of the rope section leading to the loop which comprises part of the core, preferably the entire core. | 05-07-2015 |